Business Wire

OnProcess Exceeds All Financial Expectations for FY21-22 and Drives Forward on a Circular Mission

1.6.2022 15:00:00 EEST | Business Wire | Press release

Share

OnProcess Technology, a global pioneer powering the world’s circular service value chains, today announced the results of its 2022 financial year to shareholders, reporting success across all four ‘pillars’ of the company’s strategy, and defining a new ‘digital first’ direction for the company.

From a financial perspective, OnProcess highlighted a very strong year, finishing well ahead of revenue expectations and EBITDA targets. It also reported a 109% growth in revenues from existing customers against the lowest churn rate for many years, and an increase in customer Net Promoter Score (NPS) to 57.6.

OnProcess also confirmed the closing of a substantial investment round which will be used to further boost the technology and product roadmap as well as developing new sales and marketing capabilities into new market sectors.

OnProcess also highlighted the development and launch of its flagship digital platform, OnProcess Agora™ during the financial year, along with the first new application built on it, Agora Recover™, aimed at digitalizing the returns process, improving customer experience and satisfaction levels, and setting the path towards more sustainable, circular service supply chains. OnProcess Agora now forms the basis of all new customer implementations and the new digitalization direction set by the company – a transformational approach that not only applies digital efficiency to its customers’ processes but entirely new ways of running those processes and delivering new end-customer experiences.

The company also revealed some of its plans for the new financial year 2022-23, highlighting new product offerings under development as well as expansion into new market segments. To help drive those product innovations, the company announced the appointment of its first Chief Product Officer. Other focus areas for FY23 would be to drive the continued adoption of the Agora platform from existing customer migrations as well as new customer and account growth. It also announced further investment in talent as well as cementing the company’s stance on diversity, equity, and inclusion (DEI) and a commitment around certain social responsibility initiatives on sustainability and circular economy metrics for the company as well as for its customers.

“I am immensely proud of what the OnProcess team has achieved this year and would like to thank all of them for their efforts in delivering what has been a very successful year for OnProcess,” said Oliver Lemanski, CEO of OnProcess. “We have surpassed every goal set against our transformational strategy and exceeded all financial targets, all with a backdrop of continued global uncertainty from the Covid-19 pandemic and supply chain challenges for our customers. A successful year by any measure, but perhaps even more importantly one that shows that our strategic path of a new ‘digital-first’ OnProcess, is indeed the right one.”

About OnProcess Technology , Inc.

OnProcess supplies technology and services that power the world’s circular service supply chains. Providing managed services and digital transformation expertise that streamlines processes, maximizes customer lifetime value, and improves ‘circular’ sustainability goals, OnProcess is a trusted advisor to many of the world’s leading computer, networking, med-tech, wireless, telecommunications, and IT companies.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Marta Marinova
OnProcess Technology, Inc.
mmarinova@onprocess.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release

A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release

Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release

Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study

Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release

Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye